These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3950042)

  • 21. NADH-ferric reductase activity associated with dihydropteridine reductase.
    Lee PL; Halloran C; Cross AR; Beutler E
    Biochem Biophys Res Commun; 2000 May; 271(3):788-95. PubMed ID: 10814540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tetrahydrobiopterin metabolism in the Rett disease.
    Sahota A; Leeming R; Blair J; Hagberg B
    Brain Dev; 1985; 7(3):249-50. PubMed ID: 4061756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dihydropteridine reductase activity in leukocytes and cultured fibroblasts of health individuals and of patients with the classical form of phenylketonuria].
    Gromov PS; Val'iano NM; Akhunov VS; Annenkov GA
    Vopr Med Khim; 1983; 29(5):66-9. PubMed ID: 6649535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two mutations of dihydropteridine reductase deficiency.
    Ponzone A; Guardamagna O; Ferraris S; Bracco G; Niederwieser A; Cotton RG
    Arch Dis Child; 1988 Feb; 63(2):154-7. PubMed ID: 2894818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Diagnosis, treatment and gene mutation analysis of the first case with dihydropteridine reductase deficiency in the mainland of China].
    Ye J; Qiu WJ; Han LS; Zhang HW; Zhou JD; Gao XL; Wang Y; Gu XF
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):281-5. PubMed ID: 19099731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disturbance of cerebral function by aluminium in haemodialysis patients without overt aluminium toxicity.
    Altmann P; Dhanesha U; Hamon C; Cunningham J; Blair J; Marsh F
    Lancet; 1989 Jul; 2(8653):7-12. PubMed ID: 2567838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Partial purification of dihydropteridine reductase from rat erythrocytes (author's transl)].
    Hirayama ST; Nakanishi N; Katoh S; Tachiawa A; Yamada S
    Josai Shika Daigaku Kiyo; 1980; 1(9):11-5. PubMed ID: 6940630
    [No Abstract]   [Full Text] [Related]  

  • 28. Dihydropteridine reductase activity and neopterin levels in leukemias and lymphomas: is there any correlation between these two parameters?
    Altindag ZZ; Sahin G; Işimer A; Akpek G; Kansu E
    Leuk Lymphoma; 1999 Oct; 35(3-4):367-74. PubMed ID: 10706461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activities of cerebral dihydropteridine reductase and tyrosine hydroxylase in chronic uremia in rats.
    Mullen BJ; Wang M
    J Nutr; 1986 Jul; 116(7):1298-305. PubMed ID: 2875142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative structure-activity relationship study on some dihydropteridine reductase inhibitors.
    Babbar R; Gupta JK; Gupta SP
    J Enzyme Inhib; 1989; 2(4):231-7. PubMed ID: 2723771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The time-dependent inactivation of human brain dihydropteridine reductase by the oxidation products of L-dopa.
    Waring P
    Eur J Biochem; 1986 Mar; 155(2):305-10. PubMed ID: 3956487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical (mild) forms of dihydropteridine reductase deficiency: neurochemical evaluation and mutation detection.
    Blau N; Heizmann CW; Sperl W; Korenke GC; Hoffmann GF; Smooker PM; Cotton RG
    Pediatr Res; 1992 Dec; 32(6):726-30. PubMed ID: 1283784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-level expression of human dihydropteridine reductase (EC 1.6.99.7), without N-terminal amino acid protection, in Escherichia coli.
    Armarego WL; Cotton RG; Dahl HH; Dixon NE
    Biochem J; 1989 Jul; 261(1):265-8. PubMed ID: 2673215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of dopamine autoxidation by tetrahydrobiopterin and NADH in the presence of dihydropteridine reductase.
    Shen RS
    Neurotoxicology; 1991; 12(2):201-8. PubMed ID: 1956581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythrocyte adenosine kinase activity in gout.
    Nishizawa T; Nishida Y; Akaoka I
    Clin Chim Acta; 1976 Feb; 67(1):15-20. PubMed ID: 175981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oxidase activity at the erythrocyte level].
    Pavel M; Iacobovici A; Duca A
    Rev Med Chir Soc Med Nat Iasi; 1987; 91(2):301-4. PubMed ID: 3685692
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of the metals on dihydropteridine reductase activity.
    Altindag ZZ; Baydar T; Engin AB; Sahin G
    Toxicol In Vitro; 2003; 17(5-6):533-7. PubMed ID: 14599441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydropteridine-reductase activity in breast cancer. Preliminary report.
    Dhondt JL; Bonneterre J; Farriaux JP; Lefebvre J; Demaille A
    Biomedicine; 1981 May; 35(2):58-60. PubMed ID: 6266525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnesium and potassium status in elderly subjects with and without dementia of the Alzheimer type.
    Borella P; Giardino A; Neri M; Andermarker E
    Magnes Res; 1990 Dec; 3(4):283-9. PubMed ID: 2132676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal structure of rat liver dihydropteridine reductase.
    Varughese KI; Skinner MM; Whiteley JM; Matthews DA; Xuong NH
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6080-4. PubMed ID: 1631094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.